Meeting NewsVideo

VIDEO: Abicipar pegol inflammation reduced in MAPLE study

CHICAGO — At the American Society of Retina Specialists meeting, Raj K. Maturi, MD, discusses the results of the MAPLE study of abicipar pegol (Allergan), showing that intraocular inflammation was half the amount as had occurred in the phase 3 studies of the drug due to a new manufacturing process.

CHICAGO — At the American Society of Retina Specialists meeting, Raj K. Maturi, MD, discusses the results of the MAPLE study of abicipar pegol (Allergan), showing that intraocular inflammation was half the amount as had occurred in the phase 3 studies of the drug due to a new manufacturing process.

    See more from American Society of Retina Specialists Meeting